Ontruzant 420 mg Powder for Concentrate for Solution for Infusion Vial

Ontruzant 420 mg is a highly specialized biological medicine used in the treatment of specific types of cancer. It is a biosimilar to Herceptin (trastuzumab), a monoclonal antibody designed to target and block the activity of the Human Epidermal growth factor Receptor 2 (HER2) protein. This medication is primarily indicated for patients with HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. As a critical treatment option, Ontruzant is recognized on platforms like Nahdi Online for its role in oncology care. You may also find information and related products on leading e-commerce sites such as and , where similar specialized pharmaceutical products are detailed, often with accompanying product images and descriptions featuring specific color codes for branding.

Benefits of Use

• Targeted Therapy: Ontruzant specifically targets HER2-positive cancer cells, minimizing harm to healthy cells.
• Improved Survival Rates: Clinical studies have demonstrated its effectiveness in improving progression-free and overall survival in eligible patients.
• Comprehensive Treatment: It is often used in combination with chemotherapy or other cancer therapies to provide a comprehensive treatment approach.
• Biosimilar Advantage: As a biosimilar, Ontruzant offers a high-quality, effective, and often more accessible treatment option.

How to Use

Ontruzant 420 mg is a prescription-only medicine that must be administered by a qualified healthcare professional.

1. The powder for concentrate must be reconstituted with sterile water for injection and then further diluted with 0.9% sodium chloride solution for infusion.
2. The prepared solution is administered as an intravenous infusion over a specified period, typically 30 to 90 minutes.
3. Dosage and administration frequency are determined by the patient's body weight, specific cancer type, stage, and concurrent therapies, as prescribed by an oncologist.
4. Patients are monitored closely during and after the infusion for any immediate reactions.
5. Treatment duration varies depending on the patient's response and disease progression.

Caution & Warnings

• Cardiotoxicity: Serious cardiac dysfunction, including congestive heart failure, has been reported. Regular cardiac monitoring (e.g., ECHO or MUGA scans) is essential before and during treatment.
• Infusion-Related Reactions: Patients may experience fever, chills, nausea, vomiting, pain, headache, dizziness, dyspnea, hypotension, and rash during or after infusion. Severe reactions may require discontinuation.
• Pulmonary Toxicity: Cases of severe lung toxicity, including interstitial pneumonitis and acute respiratory distress syndrome, have been reported.
• Embryo-Fetal Toxicity: Ontruzant can cause fetal harm when administered to a pregnant woman. Effective contraception must be used during treatment and for 7 months after the last dose.
• Hypersensitivity: Patients with known hypersensitivity to trastuzumab or any excipients should not use this product.
• Monitoring: Close monitoring by a physician experienced in oncology is required throughout the treatment course.

Ingredients

• Active Ingredient: Trastuzumab 420 mg
• Excipients: L-histidine, alpha,alpha-trehalose dihydrate, polysorbate 20.

Product Details

• Form: Powder for concentrate for solution for infusion
• Strength: 420 mg
• Package Type: Vial
• Manufacturer: Samsung Bioepis
• Legal Status: Prescription Only Medicine (POM)
• Storage: Store in a refrigerator (2°C - 8°C). Do not freeze. Keep the vial in the outer carton to protect from light.